SciMercor

SciMar is a Canadian biotechnology company focused on the discovery and development of hepatalin, a hormone produced by the liver that regulates glucose metabolism. The company's research is based on the Hepatic Insulin-Sensitizing Substance (HISS) hypothesis, which suggests that hepatalin deficiency is a primary driver of insulin resistance and type 2 diabetes. SciMar is developing a suite of products including diagnostic tests to measure hepatalin levels and therapeutic interventions designed to stimulate or replace the hormone. By targeting the root physiological cause of metabolic dysfunction, SciMar aims to provide earlier detection and more effective treatment for prediabetes and type 2 diabetes.